Form 8-K - Current report:
SEC Accession No. 0001193125-25-319638
Filing Date
2025-12-16
Accepted
2025-12-15 19:49:49
Documents
11
Period of Report
2025-12-15
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aldx-20251215.htm   iXBRL 8-K 68169
2 EX-99.1 aldx-ex99_1.htm EX-99.1 22013
  Complete submission text file 0001193125-25-319638.txt   212966

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aldx-20251215.xsd EX-101.SCH 30863
14 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20251215_htm.xml XML 4712
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 251573017
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)